Comparative Pharmacology
Head-to-head clinical analysis: AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE versus NATURETIN 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE versus NATURETIN 10.
AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE vs NATURETIN-10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azilsartan medoxomil is an angiotensin II receptor antagonist that selectively blocks the binding of angiotensin II to AT1 receptors, reducing vasoconstriction and aldosterone secretion. Chlorthalidone is a thiazide-like diuretic that inhibits sodium reabsorption in the distal convoluted tubule, increasing sodium and water excretion.
Bendroflumethiazide is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, increasing excretion of sodium, chloride, and water. It also reduces peripheral vascular resistance and has antihypertensive effects.
Azilsartan medoxomil 40 mg/chlorthalidone 12.5 mg or 25 mg orally once daily; maximum dose: azilsartan medoxomil 40 mg/chlorthalidone 25 mg per day.
Adults: 10 mg orally once daily.
None Documented
None Documented
Azilsartan medoxomil: Terminal half-life approximately 11 hours. Chlorthalidone: Long terminal half-life of 40-60 hours (mean 47 hours), allowing once-daily dosing.
Terminal elimination half-life is approximately 2-4 hours; clinical context: dose adjustments may be needed in renal impairment.
Azilsartan medoxomil: Approximately 55% of the dose is excreted in feces and 42% in urine, mostly as metabolites. Chlorthalidone: Primarily excreted unchanged in urine (50-70%) via tubular secretion; approximately 30% is excreted in feces via biliary elimination.
Primarily renal (approximately 50-70% as unchanged drug); biliary/fecal elimination accounts for the remainder (30-50%).
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic